nodes	percent_of_prediction	percent_of_DWPC	metapath
Methoxamine—Levonordefrin—ADRA2C—attention deficit hyperactivity disorder	0.0298	0.701	CrCbGaD
Methoxamine—Levonordefrin—ADRA2A—attention deficit hyperactivity disorder	0.0127	0.299	CrCbGaD
Methoxamine—ADRA1D—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00857	0.00929	CbGpPWpGaD
Methoxamine—ADRA1B—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0084	0.0091	CbGpPWpGaD
Methoxamine—ADRA1D—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00822	0.00891	CbGpPWpGaD
Methoxamine—ADRA1B—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.00812	0.0088	CbGpPWpGaD
Methoxamine—ADRA1D—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00796	0.00863	CbGpPWpGaD
Methoxamine—ADRA1B—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.00786	0.00852	CbGpPWpGaD
Methoxamine—ADRA1D—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00783	0.00849	CbGpPWpGaD
Methoxamine—ADRA1A—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.00775	0.00841	CbGpPWpGaD
Methoxamine—ADRA1D—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00773	0.00838	CbGpPWpGaD
Methoxamine—ADRA1B—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.00773	0.00838	CbGpPWpGaD
Methoxamine—ADRA1B—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.00763	0.00827	CbGpPWpGaD
Methoxamine—ADRA1A—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.00746	0.00809	CbGpPWpGaD
Methoxamine—ADRA1B—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.00734	0.00796	CbGpPWpGaD
Methoxamine—ADRA1A—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.00721	0.00782	CbGpPWpGaD
Methoxamine—ADRA1D—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.0072	0.00781	CbGpPWpGaD
Methoxamine—ADRA1B—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00711	0.00771	CbGpPWpGaD
Methoxamine—ADRA1A—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.00698	0.00757	CbGpPWpGaD
Methoxamine—ADRA1A—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.00686	0.00744	CbGpPWpGaD
Methoxamine—ADRA1B—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00682	0.0074	CbGpPWpGaD
Methoxamine—ADRA1A—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.00678	0.00735	CbGpPWpGaD
Methoxamine—ADRA1B—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00661	0.00716	CbGpPWpGaD
Methoxamine—ADRA1A—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.00652	0.00707	CbGpPWpGaD
Methoxamine—ADRA1B—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00649	0.00704	CbGpPWpGaD
Methoxamine—ADRA1B—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00641	0.00696	CbGpPWpGaD
Methoxamine—ADRA1A—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00631	0.00685	CbGpPWpGaD
Methoxamine—ADRA1A—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00606	0.00657	CbGpPWpGaD
Methoxamine—ADRA1D—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.006	0.0065	CbGpPWpGaD
Methoxamine—ADRA1B—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00598	0.00648	CbGpPWpGaD
Methoxamine—ADRA1A—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00587	0.00636	CbGpPWpGaD
Methoxamine—ADRA1A—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00577	0.00626	CbGpPWpGaD
Methoxamine—ADRA1A—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.0057	0.00618	CbGpPWpGaD
Methoxamine—ADRA1D—forebrain—attention deficit hyperactivity disorder	0.0057	0.161	CbGeAlD
Methoxamine—ADRA1A—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00531	0.00576	CbGpPWpGaD
Methoxamine—ADRA1D—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00504	0.00547	CbGpPWpGaD
Methoxamine—ADRA1B—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00498	0.0054	CbGpPWpGaD
Methoxamine—ADRA1A—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00442	0.0048	CbGpPWpGaD
Methoxamine—ADRA1D—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00421	0.00456	CbGpPWpGaD
Methoxamine—ADRA1B—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00419	0.00454	CbGpPWpGaD
Methoxamine—ADRA1D—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00408	0.00443	CbGpPWpGaD
Methoxamine—ADRA1A—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00372	0.00403	CbGpPWpGaD
Methoxamine—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00342	0.00371	CbGpPWpGaD
Methoxamine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00335	0.00363	CbGpPWpGaD
Methoxamine—ADRA1D—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00335	0.00363	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00333	0.00361	CbGpPWpGaD
Methoxamine—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.00327	0.0927	CbGeAlD
Methoxamine—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.00316	0.0895	CbGeAlD
Methoxamine—ADRA1D—nervous system—attention deficit hyperactivity disorder	0.00309	0.0876	CbGeAlD
Methoxamine—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.00304	0.0862	CbGeAlD
Methoxamine—ADRA1D—central nervous system—attention deficit hyperactivity disorder	0.00298	0.0843	CbGeAlD
Methoxamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00293	0.00318	CbGpPWpGaD
Methoxamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00287	0.00311	CbGpPWpGaD
Methoxamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00284	0.00308	CbGpPWpGaD
Methoxamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00278	0.00302	CbGpPWpGaD
Methoxamine—ADRA1B—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00278	0.00301	CbGpPWpGaD
Methoxamine—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.00277	0.0784	CbGeAlD
Methoxamine—ADRA1B—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00276	0.00299	CbGpPWpGaD
Methoxamine—ADRA1D—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00266	0.00289	CbGpPWpGaD
Methoxamine—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00252	0.00273	CbGpPWpGaD
Methoxamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00247	0.00268	CbGpPWpGaD
Methoxamine—ADRA1A—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00247	0.00268	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00245	0.00266	CbGpPWpGaD
Methoxamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00243	0.00264	CbGpPWpGaD
Methoxamine—ADRA1B—brain—attention deficit hyperactivity disorder	0.00242	0.0684	CbGeAlD
Methoxamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00238	0.00258	CbGpPWpGaD
Methoxamine—ADRA1D—brain—attention deficit hyperactivity disorder	0.00236	0.0669	CbGeAlD
Methoxamine—ADRA1D—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00232	0.00252	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00223	0.00242	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00219	0.00237	CbGpPWpGaD
Methoxamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00216	0.00234	CbGpPWpGaD
Methoxamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00212	0.00229	CbGpPWpGaD
Methoxamine—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00203	0.0022	CbGpPWpGaD
Methoxamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00199	0.00216	CbGpPWpGaD
Methoxamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00193	0.00209	CbGpPWpGaD
Methoxamine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00189	0.00205	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00188	0.00204	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00185	0.00201	CbGpPWpGaD
Methoxamine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00183	0.00198	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00181	0.00197	CbGpPWpGaD
Methoxamine—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.0018	0.00195	CbGpPWpGaD
Methoxamine—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.00178	0.0503	CbGeAlD
Methoxamine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00177	0.00192	CbGpPWpGaD
Methoxamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00174	0.00189	CbGpPWpGaD
Methoxamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00171	0.00186	CbGpPWpGaD
Methoxamine—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.00171	0.0484	CbGeAlD
Methoxamine—ADRA1D—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00171	0.00185	CbGpPWpGaD
Methoxamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00168	0.00183	CbGpPWpGaD
Methoxamine—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.00167	0.0473	CbGeAlD
Methoxamine—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00165	0.00179	CbGpPWpGaD
Methoxamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00165	0.00179	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00164	0.00178	CbGpPWpGaD
Methoxamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00162	0.00175	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00161	0.00175	CbGpPWpGaD
Methoxamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00157	0.0017	CbGpPWpGaD
Methoxamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00157	0.0017	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00156	0.00169	CbGpPWpGaD
Methoxamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00154	0.00167	CbGpPWpGaD
Methoxamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00152	0.00165	CbGpPWpGaD
Methoxamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00152	0.00164	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00152	0.00164	CbGpPWpGaD
Methoxamine—ADRA1D—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.0015	0.00162	CbGpPWpGaD
Methoxamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0015	0.00162	CbGpPWpGaD
Methoxamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00149	0.00162	CbGpPWpGaD
Methoxamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00147	0.0016	CbGpPWpGaD
Methoxamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00147	0.00159	CbGpPWpGaD
Methoxamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00144	0.00157	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00142	0.00154	CbGpPWpGaD
Methoxamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00142	0.00154	CbGpPWpGaD
Methoxamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00139	0.00151	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00139	0.0015	CbGpPWpGaD
Methoxamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00137	0.00149	CbGpPWpGaD
Methoxamine—ADRA1A—brain—attention deficit hyperactivity disorder	0.00136	0.0385	CbGeAlD
Methoxamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00135	0.00146	CbGpPWpGaD
Methoxamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00134	0.00146	CbGpPWpGaD
Methoxamine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00134	0.00145	CbGpPWpGaD
Methoxamine—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00132	0.00144	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00132	0.00144	CbGpPWpGaD
Methoxamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00131	0.00142	CbGpPWpGaD
Methoxamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.0013	0.00141	CbGpPWpGaD
Methoxamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00128	0.00139	CbGpPWpGaD
Methoxamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00128	0.00139	CbGpPWpGaD
Methoxamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00126	0.00137	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00126	0.00137	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00126	0.00136	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00126	0.00136	CbGpPWpGaD
Methoxamine—ADRA1B—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00124	0.00135	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00124	0.00134	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00123	0.00134	CbGpPWpGaD
Methoxamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00122	0.00132	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00119	0.00129	CbGpPWpGaD
Methoxamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00119	0.00129	CbGpPWpGaD
Methoxamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00118	0.00127	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00117	0.00127	CbGpPWpGaD
Methoxamine—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00116	0.00126	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00116	0.00126	CbGpPWpGaD
Methoxamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00115	0.00125	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00115	0.00124	CbGpPWpGaD
Methoxamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00113	0.00123	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00112	0.00122	CbGpPWpGaD
Methoxamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00112	0.00122	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00112	0.00121	CbGpPWpGaD
Methoxamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00111	0.00121	CbGpPWpGaD
Methoxamine—ADRA1A—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.0011	0.0012	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.0011	0.00119	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00108	0.00117	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00105	0.00113	CbGpPWpGaD
Methoxamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00104	0.00113	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00103	0.00111	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00102	0.00111	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00101	0.00109	CbGpPWpGaD
Methoxamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000992	0.00108	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00099	0.00107	CbGpPWpGaD
Methoxamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000987	0.00107	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000976	0.00106	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000973	0.00105	CbGpPWpGaD
Methoxamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000961	0.00104	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000961	0.00104	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00095	0.00103	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000931	0.00101	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00093	0.00101	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000911	0.000988	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000908	0.000984	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000895	0.000971	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000879	0.000953	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000864	0.000937	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000856	0.000928	CbGpPWpGaD
Methoxamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000853	0.000925	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000853	0.000925	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000844	0.000915	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000837	0.000908	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000827	0.000897	CbGpPWpGaD
Methoxamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000823	0.000893	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000795	0.000862	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000787	0.000854	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000778	0.000843	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000755	0.000819	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000748	0.000812	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000744	0.000806	CbGpPWpGaD
Methoxamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000731	0.000793	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000711	0.000771	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000696	0.000754	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00068	0.000737	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000676	0.000733	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000674	0.000731	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000663	0.000719	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000662	0.000718	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000654	0.000709	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000653	0.000709	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00065	0.000705	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000645	0.0007	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000632	0.000685	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000631	0.000684	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000627	0.00068	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000621	0.000674	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000612	0.000664	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000609	0.000661	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000602	0.000652	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000594	0.000644	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00058	0.000629	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000577	0.000626	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000573	0.000622	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000564	0.000612	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000561	0.000609	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000559	0.000606	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000557	0.000604	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000553	0.0006	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000552	0.000598	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00055	0.000596	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00055	0.000596	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000543	0.000589	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000539	0.000585	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000524	0.000569	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000513	0.000556	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000508	0.000551	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000506	0.000548	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000501	0.000543	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000499	0.000541	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000499	0.000541	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000497	0.000539	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000493	0.000535	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000489	0.00053	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000488	0.00053	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000482	0.000523	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000479	0.00052	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000466	0.000505	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000459	0.000498	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000459	0.000498	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000451	0.000489	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000449	0.000487	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000443	0.000481	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000438	0.000475	CbGpPWpGaD
Methoxamine—ADRA1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000427	0.000463	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000408	0.000442	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000401	0.000435	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000388	0.00042	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000381	0.000413	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000373	0.000405	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000361	0.000392	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000355	0.000385	CbGpPWpGaD
Methoxamine—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000354	0.000384	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000351	0.000381	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000339	0.000367	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000333	0.000361	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000327	0.000354	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000322	0.000349	CbGpPWpGaD
Methoxamine—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000315	0.000341	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00031	0.000336	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.0003	0.000325	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000296	0.000321	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000295	0.00032	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000291	0.000316	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000286	0.00031	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000275	0.000298	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000271	0.000294	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000267	0.000289	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000262	0.000284	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000259	0.000281	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000241	0.000261	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000229	0.000248	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00019	0.000206	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000169	0.000183	CbGpPWpGaD
Methoxamine—ADRA1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000121	0.000132	CbGpPWpGaD
Methoxamine—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000101	0.000109	CbGpPWpGaD
Methoxamine—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.94e-05	9.7e-05	CbGpPWpGaD
